VEGFA and cancer: VEGF is well accepted as the major angiogenic factor for both stem cells and cancer cells, and three classes of agents that mainly target VEGF have been developed in research or clinical practice: monoclonal antibodies, VEGF decoy receptors, and small molecule tyrosine kinase inhibitors (TKIs).